Rare multi-fungal sepsis: a case of triple-impact immunoparalysis

Bretislav Lipovy1,2, Martin Hladik1, Katerina Vyklicka3

  • 1Department of Burns and Plastic Surgery, Faculty of Medicine, Institution Shared With University Hospital Brno, Masaryk University, Jihlavska 20, Brno, Czech Republic.

Folia Microbiologica
|April 22, 2024
PubMed

Insights

A critical burn, inhalation injury, and SARS-CoV-2 infection led to a rare fungal co-infection. This triple immunoparalysis resulted in fatal septic shock, highlighting diagnostic and therapeutic challenges in critical care.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Mycology

Background:

  • Burn and inhalation injuries compromise immune defenses, increasing susceptibility to opportunistic infections.
  • Patients with severe injuries face risks from pathogens due to disrupted homeostasis and damaged barriers.
  • The interplay between critical illness, viral infection, and fungal co-infections presents complex clinical challenges.

Observation:

  • A 34-year-old male with critical burns and inhalation injury developed SARS-CoV-2 infection.
  • This triple-impact immunoparalysis led to a unique, lethal multifocal infection involving rare fungi: Metschnikowia pulcherrima and Wickerhamomyces anomalus.
  • The patient experienced refractory septic shock despite treatment with isavuconazole.

Findings:

  • This case represents the first documented co-infection of Metschnikowia pulcherrima and Wickerhamomyces anomalus in a human.
  • Despite potent antifungal therapy, the patient succumbed to the infection, suggesting potential therapeutic limitations.
  • Large distribution volume of isavuconazole in intensive care patients may impair treatment efficacy.

Implications:

  • Routine monitoring of isavuconazole plasma concentrations could aid in personalizing treatment and optimizing dosage in critical care.
  • Advanced diagnostic methods like next-generation sequencing are crucial for identifying underdiagnosed fungal co-infections.
  • Understanding triple-impact immunoparalysis is vital for improving outcomes in critically ill patients with complex infections.